{
  "source": "PA-Med-Nec-Voydeya.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2340-2\nProgram Prior Authorization/Medical Necessity\nMedication Voydeya™ (danicopan)\nP&T Approval Date 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background\nVoydeya (danicopan) is a complement factor D inhibitor indicated as add-on therapy to\nUltomiris (ravulizumab) or eculizumab for the treatment of extravascular hemolysis (EVH) in\nadults with paroxysmal nocturnal hemoglobinuria (PNH).1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Voydeya will be approved based on all of the following criteria:\na. Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as\nconfirmed by both of the following2,3,4,5:\n(1) Flow cytometry analysis confirming presence of PNH clones\n-AND-\n(2) Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal\npain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia,\nunexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease,\npulmonary hypertension, etc.)\n-AND-\nb. All of the following:\n(1) Patient is currently receiving complement protein C5 inhibitor eculizumab or\nUltomiris (ravulizumab)\n-AND-\n(2) Patient is experiencing extravascular hemolysis (EVH) while on complement\nprotein C5 inhibitor eculizumab or Ultomiris (ravulizumab)\n-AND-\n(3) Patient will continue to receive complement protein C5 inhibitor eculizumab or\nUltomiris (ravulizumab)\n© 2025 UnitedHealthcare Services Inc.\n1\n-AND-\nc. Patient is not receiving Voydeya in combination with a complement protein C3\ninhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g.,\nFabhalta (iptacopan)] used for the treatment of PNH\n-AND-\nd. Prescribed by, or in consultation with one of the following:\n(1) Hematologist\n(2) Oncologist\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Voydeya will be approved based on all of the following criteria:\na. Documentation o",
    " of the following:\n(1) Hematologist\n(2) Oncologist\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Voydeya will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Voydeya therapy [e.g., decrease in\nextravascular hemolysis (EVH), increased or stabilization of hemoglobin levels,\nreduction in transfusions, improvement in hemolysis, etc.)]\n-AND-\nb. Patient continues to receive Voydeya in combination with complement protein C5\ninhibitor eculizumab or Ultomiris (ravulizumab) for PNH\n-AND-\nc. Patient is not receiving Voydeya in combination with a complement protein C3\ninhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g.,\nFabhalta (iptacopan)] used for the treatment of PNH\n-AND-\nd. Prescribed by, or in consultation with one of the following:\n(1) Hematologist\n(2) Oncologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n4. References:\n1. Vodeya [package insert]. Boston, Massachusetts: Alexion Pharmaceuticals, Inc.; March 2024.\n2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal\nhemoglobinuria. Blood. 2005 Dec 1; 106(12): 3699–3709.\n3. Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of paroxysmal\nnocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.\n4. Sutherland DR, Keeney M, Illingworth A. Practical gu",
    "lain B, et al. Pathophysiology, diagnosis, and treatment of paroxysmal\nnocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.\n4. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity detection\nand monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B\nClin Cytom. 2012 Jul;82(4):195-208.\n5. Röth A, Maciejewski J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for\nparoxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018 Jul;101(1):3-11.\nProgram Prior Authorization/Medical Necessity - VoydeyaTM (danicopan)\nChange Control\n5/2024 New program.\n5/2025 Annual review. Updated list of C5 inhibitors by removing trade name of\nSoliris from eculizumab.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}